Advertisement
OtherArticle

Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor

Hirofumi Sato, Sei Murakami, Yusuke Horii, Go Nishimura, Ryosuke Iwai, Moritaka Goto and Naoki Takahashi
Molecular Pharmacology August 5, 2022, MOLPHARM-AR-2022-000522; DOI: https://doi.org/10.1124/molpharm.122.000522
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherArticle

Upacicalcet binds to the amino acid binding site of CaSR

Hirofumi Sato, Sei Murakami, Yusuke Horii, Go Nishimura, Ryosuke Iwai, Moritaka Goto and Naoki Takahashi
Molecular Pharmacology August 5, 2022, MOLPHARM-AR-2022-000522; DOI: https://doi.org/10.1124/molpharm.122.000522
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement